Board Change • Jan 28
Less than half of directors are independent There are 11 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CEO, Director of Capital Markets & Director Nick Karos is the most experienced director on the board, commencing their role in 2022. Independent Director James Duncan was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Sep 24
Universal Ibogaine Inc. Announces Board Resignations Universal Ibogaine Inc. Board of directors brings together expertise in healthcare, clinical trials, financial, and legal patient safety ensuring a strong foundation to guide the company through its next phase with confidence. As part of the transition, Peter Vlahos, Constantine Buzunis, and Peter Ginakes will no longer be part of the Board of Directors and have resigned. Universal Ibogaine confirms its Board member list of Eric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, Nick Karos as the organization advances toward submitting its clinical trial application to Health Canada by the end of November 2025. Announcement • Sep 04
Universal Ibogaine Inc. Announces Board Appointments, Effective August 28, 2025 Universal Ibogaine Inc. appointed two new Directors to join the Board, effective August 28, 2025, with one of the Board members filling a vacant Board position which previously arose in July 2025. The two new Board members are Nia Killebrew and Tony Wagner, who have joined the current Board members Nick Karos (CEO), James Duncan, and Dean Koumontzis. Bio information for Ms. Killebrew and Mr. Wagner are contained in UIs Management Information Circular dated July 23, 2025 (the Circular), which has been provided by UI in connection with the upcoming Annual Meeting of Shareholders (the AGM) which is to occur on September 4, 2025. Mr. Koumontzis is not standing for re-election to the Board at the AGM. 
